Liquidia Corporation (LQDA)

NASDAQ: LQDA · IEX Real-Time Price · USD
15.07
-0.85 (-5.34%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Company Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.

Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.

The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD.

Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Liquidia Corporation
Liquidia logo
Country United States
Founded 2004
IPO Date Jul 26, 2018
Industry Biotechnology
Sector Healthcare
Employees 145
CEO Dr. Roger A. Jeffs Ph.D.

Contact Details

Address:
419 Davis Drive, Suite 100
Durham, North Carolina 27713
United States
Phone 919-328-4400
Website liquidia.com

Stock Details

Ticker Symbol LQDA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001330436
CUSIP Number 53635D202
ISIN Number US53635D2027
SIC Code 3841

Key Executives

Name Position
Dr. Roger A. Jeffs Ph.D. Chief Executive Officer and Director
Michael Kaseta Chief Operating Officer and Chief Financial Officer
Russell Schundler General Counsel and Corporate Secretary
William R. Kenan Jr. Co-Founder
Dr. Ginger Denison Co-Founder
Jennifer Almond Director of Investor Relations and Corporate Communications
Sarah Krepp SPHR Vice President of People and Culture
Jason Adair Chief Business Officer
Dr. Tushar Shah M.D. Senior Vice President of Product Development
Scott Moomaw Chief Commercial Officer

Latest SEC Filings

Date Type Title
Feb 16, 2021 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 30, 2020 15-12B Securities registration termination
Nov 20, 2020 EFFECT Notice of Effectiveness
Nov 20, 2020 EFFECT Notice of Effectiveness
Nov 20, 2020 144 Filing
Nov 18, 2020 25-NSE Filing
Nov 18, 2020 POS AM Post-Effective amendments for registration statement
Nov 18, 2020 POS AM Post-Effective amendments for registration statement
Nov 18, 2020 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Nov 18, 2020 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments